Sanofi (SNY) Competitors

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Sanofi presently has a consensus target price of $49.50, indicating a potential upside of 24.00%. Novartis has a consensus target price of $148.40, indicating a potential upside of 5.27%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than Novartis.

In the previous week, Novartis had 5 more articles in the media than Sanofi. MarketBeat recorded 17 mentions for Novartis and 12 mentions for Sanofi. Novartis' average media sentiment score of 0.73 beat Sanofi's score of 0.46 indicating that Novartis is being referred to more favorably in the news media.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.4%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.2%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis pays out 46.5% of its earnings in the form of a dividend.

Sanofi has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Novartis has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novartis has a net margin of 23.29% compared to Sanofi's net margin of 8.66%. Novartis' return on equity of 38.56% beat Sanofi's return on equity.

In the previous week, Astrazeneca had 18 more articles in the media than Sanofi. MarketBeat recorded 30 mentions for Astrazeneca and 12 mentions for Sanofi. Sanofi's average media sentiment score of 0.46 beat Astrazeneca's score of 0.34 indicating that Sanofi is being referred to more favorably in the news media.

Astrazeneca currently has a consensus target price of $206.67, indicating a potential upside of 31.71%. Sanofi has a consensus target price of $49.50, indicating a potential upside of 24.00%. Given Astrazeneca's stronger consensus rating and higher probable upside, research analysts clearly believe Astrazeneca is more favorable than Sanofi.

Astrazeneca has a net margin of 17.02% compared to Sanofi's net margin of 8.66%. Astrazeneca's return on equity of 31.45% beat Sanofi's return on equity.

Astrazeneca has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Astrazeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.4%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Sanofi has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 35.36% compared to Sanofi's net margin of 8.66%. Novo Nordisk A/S's return on equity of 58.61% beat Sanofi's return on equity.

Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Sanofi currently has a consensus price target of $49.50, indicating a potential upside of 24.00%. Novo Nordisk A/S has a consensus price target of $102.85, indicating a potential upside of 175.68%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Sanofi.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.4%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.2%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend.

In the previous week, Novo Nordisk A/S had 38 more articles in the media than Sanofi. MarketBeat recorded 50 mentions for Novo Nordisk A/S and 12 mentions for Sanofi. Sanofi's average media sentiment score of 0.46 beat Novo Nordisk A/S's score of 0.33 indicating that Sanofi is being referred to more favorably in the media.

Sanofi presently has a consensus price target of $49.50, suggesting a potential upside of 24.00%. Pfizer has a consensus price target of $28.39, suggesting a potential upside of 2.09%. Given Sanofi's stronger consensus rating and higher probable upside, research analysts clearly believe Sanofi is more favorable than Pfizer.

In the previous week, Pfizer had 38 more articles in the media than Sanofi. MarketBeat recorded 50 mentions for Pfizer and 12 mentions for Sanofi. Sanofi's average media sentiment score of 0.46 beat Pfizer's score of 0.40 indicating that Sanofi is being referred to more favorably in the media.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.4%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.2%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

14.0% of Sanofi shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.6% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sanofi has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Sanofi has a net margin of 8.66% compared to Pfizer's net margin of 6.80%. Pfizer's return on equity of 19.63% beat Sanofi's return on equity.

Sanofi has higher earnings, but lower revenue than Pfizer. Sanofi is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.